Eli Lilly stock: Wells Fargo keeps USD 1,330.00 target for Eli Lilly stock

Published on 10/20/2026 at 16:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

2026 revenue guidance is USD 85.00-87.00 billion. Eli Lilly stock costs EUR 1,156.50 on October 20, 2026, up 4.04 percent versus the Xetra close.

Wells Fargo keeps USD 1,330.00 target

Wells Fargo maintained a USD 1,330.00 target on October 15, 2026.
2026 revenue guidance is USD 85.00 billion to USD 87.00 billion.
Eli Lilly stock costs EUR 1,156.50 at Lang & Schwarz on October 20, 2026 at 4:31 p.m. CEST, 4.04 percent above the Xetra close of October 19, 2026.

Pop-Art-Comicillustration eines Wissenschaftlers mit Spritze und Insulinpen im Labor — Pop-Art-Comicszene mit Wissenschaftler symbolisiert Eli Lilly and Company, ISIN US5324571083, kreativ im Pharmabereich humorvoll, Illustration mit AI erstellt.

Wells Fargo maintained its Buy rating and a USD 1,330.00 price target for Eli Lilly on October 15, 2026, according to Markets Insider. The company also has 2026 revenue guidance of USD 85.00 billion to USD 87.00 billion, while its stock was trading at EUR 1,156.50 at Lang & Schwarz on October 20, 2026 at 4:31 p.m. CEST, up 4.04 percent versus the Xetra close of October 19, 2026 at EUR 1,111.60.

Wells Fargo target stays above the market

The Wells Fargo target sits 2.22 percent above Eli Lilly's USD 1,301.11 NYSE price at 10:35 a.m. ET on October 20, 2026. The target and rating were maintained rather than raised, making the gap a valuation reference rather than a new forecast. Markets Insider also reported a consensus target of USD 1,366.05.

The 52-week range leaves little headroom

In euros, Eli Lilly's 52-week range is EUR 685.50 to EUR 1,160.00 as of October 20, 2026. The Lang & Schwarz price is 0.30 percent below that high, placing the stock near the upper end of its recent range. The primary-market quote was USD 1,301.11, with a market capitalization of USD 1.2 trillion and a price-to-earnings ratio of 43.66.

October 29 is the next company date

Eli Lilly's next earnings call is scheduled for October 29, 2026, at 10:00 a.m. EDT, according to Eli Lilly and Company. The latest guidance range followed second-quarter results that lifted the revenue outlook from USD 82.00 billion to USD 85.00 billion to the current USD 85.00 billion to USD 87.00 billion range, as reported by Yahoo Finance.

Price holds near the yearly high

The euro quotation is 4.04 percent above the Xetra close of October 19, 2026. The combination of a maintained USD 1,330.00 target, a scheduled October 29 report and a price near the EUR 1,160.00 yearly high leaves the upcoming earnings release as the next dated test for the valuation.

The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.